Showing results (271-280 of 302) with videos related to

Sort By:
Pageof 31
Nature Communications|April 28, 2022
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cellsTianyu Cai, Agnès Gouble, Kathryn L Black, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
American Journal of Hematology|May 31, 2017
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemiaElias Jabbour, Naval Guastad Daver, Nicholas James Short, et al.
The Oncologist|August 28, 2020
A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium StudyLi Yu, Menghan Shi, Qingqing Cai, et al.
The Lancet. Haematology|March 16, 2025
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 studyHasmukh Jain, Atharva Karulkar, Devanshi Kalra, et al.
Journal of Critical Care|May 4, 2020
The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicitiesCristina Gutierrez, Anne Rain T Brown, Megan M Herr, et al.
JAMA Oncology|July 11, 2024
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled TrialChelsea C Pinnix, Bouthaina S Dabaja, Jillian R Gunther, et al.
Blood|February 23, 2023
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Armin Ghobadi, et al.
American Journal of Cancer Research|October 13, 2022
Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-upWanying Liu, Qingqing Cai, Tiantian Yu, et al.
Pageof 31